Table 2.
Univariate and multivariate meta-regression.
| Gene | Samples | Univariate Meta-Regression | Multivariate Meta-Regression | ||||
|---|---|---|---|---|---|---|---|
| Estimate | Standard Error | p | Estimate | Standard Error | p | ||
| TP53 | Tumor site: Primary tumors | 1 (ref) | - | ||||
| Extracerebral metastases | −0.42 | 0.27 | 0.11 | ||||
| Brain metastases | 0.44 | 0.27 | 0.1 | ||||
| Quality of studies (good) | −0.29 | 0.24 | 0.22 | ||||
| Method analysis: NGS | 1 (ref) | - | - | ||||
| Targeted NGS | 0.24 | 0.25 | 0.33 | ||||
| Other | −0.5 | 0.47 | 0.28 | ||||
| Preservation (Frozen) | −0.25 | 0.29 | 0.39 | ||||
| BRCA2 | Tumor site: Primary tumors | 1 (ref) | - | - | 1 (ref) | - | - |
| Extracerebral metastases | −0.24 | 0.35 | 0.49 | −0.12 | 0.41 | 0.77 | |
| Brain metastases | 0.94 | 0.35 | 0.008 | 0.92 | 0.37 | 0.01 | |
| Quality of studies (good) | −0.79 | 0.44 | 0.07 | ||||
| Method analysis: NGS | 1 (ref) | - | - | ||||
| Targeted NGS | −0.29 | 0.4 | 0.48 | ||||
| Other | - | - | - | ||||
| Preservation (Frozen) | −0.87 | 0.66 | 0.19 | −0.59 | 0.58 | 0.31 | |
| PTEN | Tumor site: Primary tumors | 1 (ref) | - | - | 1 (ref) | - | - |
| Extracerebral metastases | 0.46 | 0.32 | 0.15 | 0.47 | 0.29 | 0.1 | |
| Brain metastases | 0.84 | 0.35 | 0.01 | 0.32 | 0.35 | 0.36 | |
| Quality of studies (good) | −1.26 | 0.32 | <0.0001 | −1.21 | 0.37 | 0.01 | |
| Method analysis: NGS | 1 (ref) | - | - | ||||
| Targeted NGS | −0.41 | 0.38 | 0.27 | ||||
| Other | −0.58 | 0.78 | 0.45 | ||||
| Preservation (Frozen) | 0.88 | 0.37 | 0.01 | 0.23 | 0.36 | 0.52 | |
| NRAS | Tumor site: Primary tumors | 1 (ref) | - | - | 1 (ref) | - | - |
| Extracerebral metastases | −3.81 | 1.12 | 0.0007 | −3.05 | 0.88 | 0.0005 | |
| Brain metastases | 0.88 | 0.89 | 0.32 | 0.65 | 0.71 | 0.35 | |
| Quality of studies (good) | −3.42 | 1.11 | 0.002 | −1.95 | 0.64 | 0.002 | |
| Method analysis: NGS | 1 (ref) | - | - | ||||
| Targeted NGS | - | - | - | ||||
| Other | −1.62 | 2.38 | 0.49 | ||||
| Preservation (Frozen) | - | - | - | ||||
| NOTCH1 | Tumor site: Primary tumors | 1 (ref) | - | - | 1 (ref) | - | - |
| Extracerebral metastases | −3.55 | 1.18 | 0.002 | −2.97 | 1.1 | 0.006 | |
| Brain metastases | 1.46 | 0.87 | 0.09 | 1.5 | 0.76 | 0.04 | |
| Quality of studies (good) | −1.52 | 1.09 | 0.16 | −0.39 | 0.81 | 0.62 | |
| Method analysis: NGS | 1 (ref) | - | - | 1 (ref) | - | - | |
| Targeted NGS | 1.8 | 0.99 | 0.07 | 1.04 | 0.75 | 0.16 | |
| Other | - | - | - | - | - | - | |
| Preservation (Frozen) | 1.12 | 1.21 | 0.35 | ||||
| EGFR | Tumor site: Primary tumors | 1 (ref) | - | - | 1 (ref) | - | - |
| Extracerebral metastases | −1.89 | 0.78 | 0.01 | −1.42 | 0.39 | 0.0003 | |
| Brain metastases | 1.38 | 0.61 | 0.02 | 1.46 | 0.44 | 0.001 | |
| Quality of studies (good) | −1.83 | 0.77 | 0.01 | −1.49 | 0.46 | 0.001 | |
| Method analysis: NGS | 1 (ref) | - | - | ||||
| Targeted NGS | 0.33 | 0.79 | 0.67 | ||||
| Other | - | - | - | ||||
| Preservation (Frozen) | −0.99 | 1.67 | 0.55 | ||||
Uni- and multivariate meta-regressions were run to assess sample groups significantly associated with prevalence of gene mutations. Sample groups yielding p-values under 0.20 in the univariate analysis were considered for inclusion in the multivariate analysis. Bold = significant p-value at the threshold of 0.05.